ChloroquineV1, Main, Exploration, bibRecord, 001B45

High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors

Identifieur interne : 001B45 ( Main/Exploration ); précédent : 001B44; suivant : 001B46

High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors

Auteurs : Cecilia P. Chung [États-Unis] ; Ingrid Avalos [États-Unis] ; Annette Oeser [États-Unis] ; Tebeb Gebretsadik [États-Unis] ; Ayumi Shintani [États-Unis] ; Paolo Raggi [États-Unis] ; C. Michael Stein [États-Unis]

Source :

Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2007-02.

RBID : ISTEX:4274E0534F524C10E74698BF9CF25D858E7F637B

English descriptors

Abstract

Background: The metabolic syndrome is an independent risk factor for ischaemic heart disease. Patients with systemic lupus erythematosus (SLE) have accelerated atherosclerosis; however, there are no controlled studies of the metabolic syndrome in patients with SLE. Objective: To compare the prevalence of the metabolic syndrome in patients with SLE and controls and to evaluate its relationship to other cardiovascular risk factors and inflammation. Methods: 102 patients with SLE and 101 controls were studied. The prevalence of the metabolic syndrome was compared in patients and controls using the National Cholesterol Education Program Adult Treatment Panel III (NCEP) and the World Health Organization (WHO) definitions, and associations with cardiovascular risk factors and lupus characteristics were examined. Results: The metabolic syndrome was present in 32.4% of patients and in 10.9% of controls subjects (p<0.001) using the WHO definition that requires direct determination of insulin resistance, and in 29.4% of patients with SLE and in 19.8% of controls (p = 0.14) using the NCEP definition. Among patients with SLE, both definitions were significantly associated with higher concentrations of C reactive protein (p = 0.001) and the NCEP definition was significantly associated with higher concentrations of homocysteine (p<0.001), lipoprotein (a) (p = 0.02) and cholesterol (p = 0.04). Neither lupus disease activity nor damage scores were associated with the metabolic syndrome. Conclusions: Patients with SLE have a higher prevalence of insulin resistance and consequently of the WHO-defined metabolic syndrome than controls. In patients with SLE, the metabolic syndrome was associated with higher levels of inflammation and may provide a link between inflammation and increased cardiovascular risk.

Url:

https://api.istex.fr/ark:/67375/NVC-K2DPQ67S-X/fulltext.pdf

DOI: 10.1136/ard.2006.054973

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 002974
to stream Istex, to step Curation: 002974
to stream Istex, to step Checkpoint: 000A28
to stream Main, to step Merge: 001B56
to stream Main, to step Curation: 001B45

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors</title>
<author><name sortKey="Chung, Cecilia P" sort="Chung, Cecilia P" uniqKey="Chung C" first="Cecilia P" last="Chung">Cecilia P. Chung</name>
</author>
<author><name sortKey="Avalos, Ingrid" sort="Avalos, Ingrid" uniqKey="Avalos I" first="Ingrid" last="Avalos">Ingrid Avalos</name>
</author>
<author><name sortKey="Oeser, Annette" sort="Oeser, Annette" uniqKey="Oeser A" first="Annette" last="Oeser">Annette Oeser</name>
</author>
<author><name sortKey="Gebretsadik, Tebeb" sort="Gebretsadik, Tebeb" uniqKey="Gebretsadik T" first="Tebeb" last="Gebretsadik">Tebeb Gebretsadik</name>
</author>
<author><name sortKey="Shintani, Ayumi" sort="Shintani, Ayumi" uniqKey="Shintani A" first="Ayumi" last="Shintani">Ayumi Shintani</name>
</author>
<author><name sortKey="Raggi, Paolo" sort="Raggi, Paolo" uniqKey="Raggi P" first="Paolo" last="Raggi">Paolo Raggi</name>
</author>
<author><name sortKey="Michael Stein, C" sort="Michael Stein, C" uniqKey="Michael Stein C" first="C" last="Michael Stein">C. Michael Stein</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4274E0534F524C10E74698BF9CF25D858E7F637B</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1136/ard.2006.054973</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-K2DPQ67S-X/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002974</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002974</idno>
<idno type="wicri:Area/Istex/Curation">002974</idno>
<idno type="wicri:Area/Istex/Checkpoint">000A28</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000A28</idno>
<idno type="wicri:doubleKey">0003-4967:2007:Chung C:high:prevalence:of</idno>
<idno type="wicri:Area/Main/Merge">001B56</idno>
<idno type="wicri:Area/Main/Curation">001B45</idno>
<idno type="wicri:Area/Main/Exploration">001B45</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors</title>
<author><name sortKey="Chung, Cecilia P" sort="Chung, Cecilia P" uniqKey="Chung C" first="Cecilia P" last="Chung">Cecilia P. Chung</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee</wicri:regionArea>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Avalos, Ingrid" sort="Avalos, Ingrid" uniqKey="Avalos I" first="Ingrid" last="Avalos">Ingrid Avalos</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee</wicri:regionArea>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oeser, Annette" sort="Oeser, Annette" uniqKey="Oeser A" first="Annette" last="Oeser">Annette Oeser</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee</wicri:regionArea>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gebretsadik, Tebeb" sort="Gebretsadik, Tebeb" uniqKey="Gebretsadik T" first="Tebeb" last="Gebretsadik">Tebeb Gebretsadik</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee</wicri:regionArea>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shintani, Ayumi" sort="Shintani, Ayumi" uniqKey="Shintani A" first="Ayumi" last="Shintani">Ayumi Shintani</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee</wicri:regionArea>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Raggi, Paolo" sort="Raggi, Paolo" uniqKey="Raggi P" first="Paolo" last="Raggi">Paolo Raggi</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Section of Cardiology, Emory University School of Medicine, Atlanta, Georgia</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Michael Stein, C" sort="Michael Stein, C" uniqKey="Michael Stein C" first="C" last="Michael Stein">C. Michael Stein</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee</wicri:regionArea>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee</wicri:regionArea>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2007-02">2007-02</date>
<biblScope unit="volume">66</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="208">208</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>BMI, body mass index</term>
<term>CRP, C reactive protein</term>
<term>HDL, high-density lipoprotein</term>
<term>HOMA, homeostasis model assessment</term>
<term>LDL, low-density lipoprotein</term>
<term>NCEP, National Cholesterol Education Program Adult Treatment Panel III</term>
<term>SLE, systemic lupus erythematosus</term>
<term>WHO, World Health Organization</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Arthritis rheum</term>
<term>Atherosclerosis</term>
<term>Blood pressure</term>
<term>Cardiovascular</term>
<term>Cardiovascular risk</term>
<term>Cardiovascular risk factors</term>
<term>Central obesity</term>
<term>Chung</term>
<term>Classification criteria</term>
<term>Disease activity</term>
<term>Erythematosus</term>
<term>Exact test</term>
<term>Fasting</term>
<term>Fasting glucose</term>
<term>General population</term>
<term>Glucose</term>
<term>High blood pressure</term>
<term>Higher concentrations</term>
<term>Higher levels</term>
<term>Homa</term>
<term>Hypertension</term>
<term>Inflammation</term>
<term>Insulin</term>
<term>Insulin resistance</term>
<term>Insulin sensitivity</term>
<term>Interquartile range</term>
<term>Lipoprotein</term>
<term>Lupus</term>
<term>Metabolic</term>
<term>Metabolic score</term>
<term>Metabolic syndrome</term>
<term>Michael stein</term>
<term>National cholesterol education program</term>
<term>National cholesterol education program adult treatment panel</term>
<term>Ncep</term>
<term>Ncep criteria</term>
<term>Ncep definition</term>
<term>Oeser</term>
<term>Prevalence</term>
<term>Reactive protein</term>
<term>Regression models</term>
<term>Risk factors</term>
<term>Syndrome</term>
<term>Systemic</term>
<term>Systemic lupus</term>
<term>Systemic lupus erythematosus</term>
<term>Triglyceride</term>
<term>Vanderbilt university school</term>
<term>World health organization</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: The metabolic syndrome is an independent risk factor for ischaemic heart disease. Patients with systemic lupus erythematosus (SLE) have accelerated atherosclerosis; however, there are no controlled studies of the metabolic syndrome in patients with SLE. Objective: To compare the prevalence of the metabolic syndrome in patients with SLE and controls and to evaluate its relationship to other cardiovascular risk factors and inflammation. Methods: 102 patients with SLE and 101 controls were studied. The prevalence of the metabolic syndrome was compared in patients and controls using the National Cholesterol Education Program Adult Treatment Panel III (NCEP) and the World Health Organization (WHO) definitions, and associations with cardiovascular risk factors and lupus characteristics were examined. Results: The metabolic syndrome was present in 32.4% of patients and in 10.9% of controls subjects (p<0.001) using the WHO definition that requires direct determination of insulin resistance, and in 29.4% of patients with SLE and in 19.8% of controls (p = 0.14) using the NCEP definition. Among patients with SLE, both definitions were significantly associated with higher concentrations of C reactive protein (p = 0.001) and the NCEP definition was significantly associated with higher concentrations of homocysteine (p<0.001), lipoprotein (a) (p = 0.02) and cholesterol (p = 0.04). Neither lupus disease activity nor damage scores were associated with the metabolic syndrome. Conclusions: Patients with SLE have a higher prevalence of insulin resistance and consequently of the WHO-defined metabolic syndrome than controls. In patients with SLE, the metabolic syndrome was associated with higher levels of inflammation and may provide a link between inflammation and increased cardiovascular risk.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Géorgie (États-Unis)</li>
<li>Tennessee</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Tennessee"><name sortKey="Chung, Cecilia P" sort="Chung, Cecilia P" uniqKey="Chung C" first="Cecilia P" last="Chung">Cecilia P. Chung</name>
</region>
<name sortKey="Avalos, Ingrid" sort="Avalos, Ingrid" uniqKey="Avalos I" first="Ingrid" last="Avalos">Ingrid Avalos</name>
<name sortKey="Gebretsadik, Tebeb" sort="Gebretsadik, Tebeb" uniqKey="Gebretsadik T" first="Tebeb" last="Gebretsadik">Tebeb Gebretsadik</name>
<name sortKey="Michael Stein, C" sort="Michael Stein, C" uniqKey="Michael Stein C" first="C" last="Michael Stein">C. Michael Stein</name>
<name sortKey="Michael Stein, C" sort="Michael Stein, C" uniqKey="Michael Stein C" first="C" last="Michael Stein">C. Michael Stein</name>
<name sortKey="Oeser, Annette" sort="Oeser, Annette" uniqKey="Oeser A" first="Annette" last="Oeser">Annette Oeser</name>
<name sortKey="Raggi, Paolo" sort="Raggi, Paolo" uniqKey="Raggi P" first="Paolo" last="Raggi">Paolo Raggi</name>
<name sortKey="Shintani, Ayumi" sort="Shintani, Ayumi" uniqKey="Shintani A" first="Ayumi" last="Shintani">Ayumi Shintani</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B45 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B45 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:4274E0534F524C10E74698BF9CF25D858E7F637B
   |texte=   High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors

High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri